WM Artphoto, Maria Westling

We are a research-based company in the cancer diagnostic field. We are developing ColoNode® – a biomarker test for accurate detection and characterization, of cancer cells in lymph nodes of colorectal cancer patients.

Colorectal cancer is the third most common cancer worldwide. Half of all patients die from the disease, despite available treatments. Additional chemotherapy following surgery can reduce the risk of recurrent cancer, but the currently used methods for selecting patients for different treatment options are inaccurate and ineffective. This results in both over- and undertreatment with unnecessary human suffering and high costs.

HiloProbe is developing a highly accurate test to identify each patient’s need of treatment after surgery for colorectal cancer. Examination of lymph node tissue with ColoNode® offers clinicians a rapid, objective and accurate routine for detection of cancer cells and determination of their aggressiveness.

Hiloprobe föreläser på Cancerdagen

Den 6 oktober deltog Hiloprobe på Cancerdagen. Här kan du se hela föreläsningen. Det var Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, som på Cancerdagen talade om ett nytt lymfkörteltest för stadieindelning och...

Hiloprobe deltar på Cancerdagen

Hiloprobe deltar på Cancerdagen den 6 oktober för att presentera de nya möjligheter som deras diagnostik-kit Colonode kan ge för behandling av kolorektalcancer. Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, ska tala...

HiloProbe Awarded SEK 2 Million by Swedish Innovation Agency

HiloProbe has been granted SEK 2 million from Swedish Innovation Agency Vinnova to validate a product that detects and helps treat people with colorectal cancer. “This is an important grant for us and means we can validate our product and make it available to the...

The ColoNode product is now available for research use only

The ColoNode product is now available for research use only! Please, read more about ColoNode at www.colonode.se or click on ColoNode above. Contact us if you are interested to discuss more about ColoNode.

HiloProbe tar in miljonbelopp

Umeåbolaget HiloProbe har tagit fram en diagnostisk och prognostisk produkt för tjock- och ändtarmscancer. Nu tar man in miljonbelopp i en ny investerarrunda. – Kapitalet är avgörande för att vår produkt ska kunna nå patienterna och komma dem till nytta, säger Lina...

Funded by